Nidufexor (LMB763), a non-steroidal partial FXR agonist, was being developed for NASH, liver fibrosis, and cholestatic liver disease, but appears to have been discontinued despite seemingly promising results from a phase 2 study in NASH subjects [66]. This evidence concerns the gene NR1H4 and Hepatic fibrosis.